Blood Stream Infections

1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

bioMerieux
bioMerieuxFrance - Marcy l'Étoile
1 program
1
Rapid DiagnosticsPhase 4
M&
Merck & Co.RAHWAY, NJ
1 program
Clinical Outcomes in Candidemia Patients Based on in Vitro SusceptibilityN/A1 trial
Active Trials
NCT01077336Completed450Est. Jan 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility

Clinical Trials (1)

Total enrollment: 450 patients across 1 trials

NCT01077336Merck & Co.Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility

Clinical Outcomes in Candidemia Patients Based on in Vitro Susceptibility

Start: Jan 2010Est. completion: Jan 2011450 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space